Phase 1 Malignancy Clinical Trials
49 recruitingPhase 1
What is a Phase 1 trial?
Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.
Showing 1–20 of 49 trials
Recruiting
Phase 1
Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies
Leukemia, Lymphocytic, AcuteBlood CancerMyeloid Leukemia, Acute+8 more
National Cancer Institute (NCI)86 enrolled1 locationNCT06904066
Recruiting
Phase 1Phase 2
Evaluating Efficacy of Tivozanib (AV-951) in Biliary Tract Cancers
CholangiocarcinomaBile Duct NeoplasmBiliary Tract Malignancy
National Cancer Institute (NCI)31 enrolled1 locationNCT04645160
Recruiting
Phase 1Phase 2
Study of Lisaftoclax (APG-2575) Single Agent and Combination With Therapy in Patients Relapsed/Refractory AML
Myeloid MalignancyRelapsed/Refractory Acute Myeloid Leukaemia
Ascentage Pharma Group Inc.682 enrolled12 locationsNCT04501120
Recruiting
Phase 1Phase 2
Decitabine and Venetoclax Treatment as Maintenance Therapy in Patients Post Allograft Stem Cell Transplant
Acute Myeloid LeukemiaMyeloid Malignancy
Benjamin Tomlinson20 enrolled2 locationsNCT06129734
Recruiting
Phase 1Phase 2
A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies
Diffuse Large B Cell LymphomaChronic Lymphocytic LeukemiaNon-Hodgkin Lymphoma+6 more
BeOne Medicines614 enrolled127 locationsNCT05006716
Recruiting
Phase 1Phase 2
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
Relapsed Hematologic MalignancyRefractory Hematologic MalignancyRelapsed Primary Central Nervous System Lymphoma+1 more
Curis, Inc.152 enrolled45 locationsNCT03328078
Recruiting
Phase 1Phase 2
Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader
Non-Hodgkin LymphomaMantle Cell LymphomaFollicular Lymphoma+6 more
BeiGene146 enrolled29 locationsNCT05294731
Recruiting
Phase 1Phase 2
A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies
Refractory CancerB-cell LymphomaB-cell Malignancy+1 more
BeOne Medicines80 enrolled50 locationsNCT06634589
Recruiting
Phase 1
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Acute Myeloid LeukemiaAcute LeukemiaAML+9 more
Kura Oncology, Inc.171 enrolled45 locationsNCT06001788
Recruiting
Phase 1
CD45RA-depleted CD19-CAR T Cell Consolidation After TCRαβ+/CD19 B Cell-depleted Haploidentical Hematopoietic Cell Transplantation for Relapsed/Refractory CD19+ ALL and Lymphoma
Hematologic MalignancyRelapsed Pediatric ALLHematopoietic Cell Transplantation
St. Jude Children's Research Hospital60 enrolled1 locationNCT07257419
Recruiting
Phase 1
Feasibility and Safety of Collecting and Combining Autologous Hematopoietic Stem Cells With Chimeric Antigen Receptor (CAR) T-Cell Therapy in Subjects With Relapsed/Refractory Hematological Malignancies
Diffuse Large B Cell LymphomaAcute Lymphoblastic LeukemiaMultiple Myeloma+3 more
Joshua Sasine, MD, PhD20 enrolled1 locationNCT05887167
Recruiting
Phase 1
Trial of Novel Anti-leukemia Agents in Flu/Mel RIC Transplant for Myeloid Malignancies
Acute Myeloid LeukemiaHematologic MalignancyMyelodysplastic Syndromes+1 more
University of Alabama at Birmingham20 enrolled1 locationNCT07044544
Recruiting
Phase 1
Intensity Modulated Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients With Relapsed Hematologic Cancers Undergoing a Second Donor Stem Cell Transplant
Recurrent Adult Acute Myeloid LeukemiaPreviously Treated Myelodysplastic SyndromeRecurrent Adult Acute Lymphoblastic Leukemia+1 more
University of Chicago30 enrolled1 locationNCT02333162
Recruiting
Phase 1Phase 2
E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers
Cervical CancerAnal CancerPenile Cancer+14 more
Christian Hinrichs15 enrolled2 locationsNCT05639972
Recruiting
Phase 1
A Phase I Trial Anti-CC Chemokine Receptor 4 Chimeric Antigen Receptor T Cells (CCR4 CAR T Cells) for CCR4 Expressing T-cell Malignancies Including Peripheral T-cell Non-Hodgkin Lymphoma (PTCL) and Cutaneous T-cell Non-Hodgkin Lymphoma (CTCL)
Relapsed and/or Refractory Mature T Cell Malignancy
National Cancer Institute (NCI)60 enrolled1 locationNCT07055477
Recruiting
Phase 1
ADCX-020 for the Treatment of Patients With Locally Advanced or Metastatic Cancers
Metastatic Solid TumorsAdvanced Solid CancersAdvanced Malignancy
Adcytherix SAS290 enrolled4 locationsNCT07238075
Recruiting
Phase 1Phase 2
Phase I/II Study of CD5 CAR Engineered IL15-Transduced Cord Blood-Derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapsed/Refractory Hematological Malignances
Hematological Malignancy
M.D. Anderson Cancer Center64 enrolled1 locationNCT05110742
Recruiting
Phase 1
Safety Trial of 68Ga/177Lu-NRT6020 in FAP-Positive Advanced Solid Tumor Patients
Solid Tumor Malignancy
Chengdu New Radiomedicine Technology Co. LTD.132 enrolled2 locationsNCT06911489
Recruiting
Phase 1
A Trial of SHR-7782 for Treatment of Advanced Malignant Tumors
Advanced Malignancy
Suzhou Suncadia Biopharmaceuticals Co., Ltd.200 enrolled2 locationsNCT07123129
Recruiting
Phase 1Phase 2
EMITT-1 (ERAP Mediated Immunopeptidome Targeting Trial - 1)
Advanced Solid Malignancy
Grey Wolf Therapeutics300 enrolled29 locationsNCT06923761